CN102625842A - 用于输送生物活性rna的组合物和方法 - Google Patents

用于输送生物活性rna的组合物和方法 Download PDF

Info

Publication number
CN102625842A
CN102625842A CN2010800210226A CN201080021022A CN102625842A CN 102625842 A CN102625842 A CN 102625842A CN 2010800210226 A CN2010800210226 A CN 2010800210226A CN 201080021022 A CN201080021022 A CN 201080021022A CN 102625842 A CN102625842 A CN 102625842A
Authority
CN
China
Prior art keywords
sequence
rna
cell
biologically active
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800210226A
Other languages
English (en)
Chinese (zh)
Inventor
K.波拉科
J.费维尔
K.安沃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLSN LAB Inc
Original Assignee
Egen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egen Inc filed Critical Egen Inc
Publication of CN102625842A publication Critical patent/CN102625842A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN2010800210226A 2009-03-13 2010-03-15 用于输送生物活性rna的组合物和方法 Pending CN102625842A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16028809P 2009-03-13 2009-03-13
US16028709P 2009-03-13 2009-03-13
US61/160,287 2009-03-13
US61/160,288 2009-03-13
PCT/US2010/027365 WO2010105277A1 (en) 2009-03-13 2010-03-15 Compositions and methods for the delivery of biologically active rnas

Publications (1)

Publication Number Publication Date
CN102625842A true CN102625842A (zh) 2012-08-01

Family

ID=42728852

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800210226A Pending CN102625842A (zh) 2009-03-13 2010-03-15 用于输送生物活性rna的组合物和方法

Country Status (8)

Country Link
US (2) US8569065B2 (enExample)
EP (1) EP2406379A4 (enExample)
JP (1) JP2012520085A (enExample)
KR (1) KR20110128345A (enExample)
CN (1) CN102625842A (enExample)
AU (1) AU2010223888A1 (enExample)
CA (1) CA2755245A1 (enExample)
WO (1) WO2010105277A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130034599A1 (en) 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
US20130101512A1 (en) * 2010-03-12 2013-04-25 Chad A. Mirkin Crosslinked polynucleotide structure
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9880151B2 (en) * 2011-05-23 2018-01-30 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
WO2013096958A1 (en) * 2011-12-23 2013-06-27 Egen, Inc. Compositions and methods for the delivery of biologically active rnas
WO2013101690A1 (en) * 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
KR20160021076A (ko) * 2013-03-15 2016-02-24 테출론 인코포레이티드 스타필로코커스 아우레우스 감염의 치료를 위한 안티센스 분자
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
JP6588024B2 (ja) 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター
JP6744224B2 (ja) 2014-02-14 2020-08-19 シンヴィヴォ コーポレイション 核酸ベクターおよびその使用
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3183007B1 (en) 2014-08-19 2020-06-17 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
JP6741673B2 (ja) 2014-10-06 2020-08-19 イグジキュア, インコーポレーテッドExicure, Inc. 抗ｔｎｆ化合物
US9816080B2 (en) * 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
EP4089166A1 (en) 2016-01-27 2022-11-16 Oncorus, Inc. Oncolytic viral vectors and uses thereof
US11639371B2 (en) * 2016-02-17 2023-05-02 The Chinese University Of Hong Kong Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases
CN109414414A (zh) 2016-03-16 2019-03-01 戴维·格拉德斯通研究所 用于治疗肥胖症和/或糖尿病以及用于鉴定候选治疗剂的方法和组合物
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
KR20200042904A (ko) 2017-07-26 2020-04-24 온코루스, 인크. 종양용해성 바이러스 벡터 및 그의 용도
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
EP3818167A4 (en) * 2018-07-05 2022-04-13 The Regents of The University of California COMPOSITIONS AND METHODS FOR DELIVERING RNA TO A CELL
US20250263690A1 (en) * 2022-06-15 2025-08-21 Duke University Protein library display systems and methods thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060101A2 (en) * 2002-01-11 2003-07-24 University Of Southern California Gene delivery system and methods of use
CN1620464A (zh) * 2001-12-20 2005-05-25 遗传和生物技术工程中心 用于治疗人乳头状瘤病毒相关性癌症和其他上皮性肿瘤的肽
US20050260756A1 (en) * 2003-01-28 2005-11-24 Troy Carol M Complex for facilitating delivery of dsRNA into a cell and uses thereof
CN1940074A (zh) * 2006-08-07 2007-04-04 汪运山 胃癌靶向AFP基因的siRNAs表达载体的构建、筛选及其用途
WO2007126386A1 (en) * 2006-05-03 2007-11-08 Loetvall Jan Olof Exosome transfer of nucleic acids to cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585263A (en) * 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US20040241845A1 (en) * 1998-05-22 2004-12-02 Luc Desgroseillers Mammalian staufen and use thereof
JP2002533128A (ja) * 1998-12-31 2002-10-08 アドバンスド リサーチ アンド テクノロジー インスティテュート アデノ随伴ウイルス２による感染のためのコレセプターとしてのヒト線維芽細胞増殖因子レセプター１
WO2002027031A2 (en) * 2000-09-28 2002-04-04 Cellomics, Inc. Methods and reagents for live-cell gene expression quantification
US20040005593A1 (en) * 2002-03-06 2004-01-08 Rigel Pharmaceuticals, Inc. Novel method for delivery and intracellular synthesis of siRNA molecules
US20050074865A1 (en) * 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
AU2003279004B2 (en) * 2002-09-28 2009-10-08 Massachusetts Institute Of Technology Influenza therapeutic
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
CN101415816A (zh) * 2006-02-02 2009-04-22 雷格内泰克公司 表征生物活性化合物的方法
CA2638915A1 (en) * 2006-02-10 2007-08-23 The Regents Of The University Of California Transducible delivery of sirna by dsrna binding domain fusions to ptd/cpps
JP2010517587A (ja) * 2007-02-15 2010-05-27 ディーエスエム アイピー アセッツ ビー．ブイ． 関心のある化合物を生産するための組み換え宿主細胞
ES2562817T3 (es) * 2010-02-24 2016-03-08 Arrowhead Research Corporation Composiciones para el suministro dirigido de ARNip

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1620464A (zh) * 2001-12-20 2005-05-25 遗传和生物技术工程中心 用于治疗人乳头状瘤病毒相关性癌症和其他上皮性肿瘤的肽
WO2003060101A2 (en) * 2002-01-11 2003-07-24 University Of Southern California Gene delivery system and methods of use
US20050260756A1 (en) * 2003-01-28 2005-11-24 Troy Carol M Complex for facilitating delivery of dsRNA into a cell and uses thereof
WO2007126386A1 (en) * 2006-05-03 2007-11-08 Loetvall Jan Olof Exosome transfer of nucleic acids to cells
CN1940074A (zh) * 2006-08-07 2007-04-04 汪运山 胃癌靶向AFP基因的siRNAs表达载体的构建、筛选及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAI等: "Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma", 《MOLECULAR THERAPY》 *

Also Published As

Publication number Publication date
US20100233141A1 (en) 2010-09-16
WO2010105277A1 (en) 2010-09-16
AU2010223888A1 (en) 2011-10-06
CA2755245A1 (en) 2010-09-16
US20140005254A1 (en) 2014-01-02
JP2012520085A (ja) 2012-09-06
US8569065B2 (en) 2013-10-29
EP2406379A4 (en) 2012-09-26
EP2406379A1 (en) 2012-01-18
KR20110128345A (ko) 2011-11-29

Similar Documents

Publication Publication Date Title
CN102625842A (zh) 用于输送生物活性rna的组合物和方法
CN104169419A (zh) 用于输送生物活性rna的组合物和方法
CN108601821B (zh) 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
KR20210021473A (ko) 푸소솜 조성물 및 그의 용도
JP2024099582A (ja) アルブミン遺伝子座からの導入遺伝子発現のための組成物及び方法
CA3120282A1 (en) Fusosome compositions for hematopoietic stem cell delivery
EP4045637A1 (en) Engineered muscle targeting compositions
CA3120082A1 (en) Fusosome compositions for cns delivery
US20240408192A1 (en) Modified paramyxoviridae attachment glycoproteins
WO2023115039A2 (en) Modified paramyxoviridae fusion glycoproteins
CA3120103A1 (en) Fusosome compositions for t cell delivery
KR20230044420A (ko) 바이러스 푸소좀을 생산하기 위한 방법 및 조성물
JP2024505678A (ja) 免疫療法のためのリンパ球活性化遺伝子３（ｌａｇ３）組成物及び方法
WO2024064838A1 (en) Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
EP4547821A1 (en) Engineered t cells
Berdeckaa et al. Non-viral delivery of RNA for therapeutic T cell engineering ex vivo
WO2025011467A1 (zh) 工程化的哺乳动物基因写入系统
WO2024220574A1 (en) Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024220560A1 (en) Engineered protein g fusogens and related lipid particles and methods thereof
WO2025049631A1 (en) Allogeneic car-t cell therapies and manufacture thereof
JP2024526878A (ja) 調節されたウイルス送達システムおよびその使用
WO2023081926A1 (en) Delta protocadherin therapies
CN120290483A (zh) 靶向msln嵌合抗原受体巨噬细胞及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CLSN LABORATORIES, INC.

Free format text: FORMER OWNER: EGEN INC.

Effective date: 20150203

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150203

Address after: Delaware

Applicant after: CLSN LAB INC

Address before: alabama

Applicant before: Expression Genetics Inc.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120801